|Day Low/High||0.02 / 0.02|
|52 Wk Low/High||0.00 / 0.04|
Gaithersburg, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc.
Gaithersburg, MD, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc.
Gaithersburg, MD, July 08, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS) is pleased to announce that it has strengthened its capital structure via a $605,000 fixed-rate convertible note from Eagle Equities, LLC.
And the winners so far outnumber the losers among the six stocks that include a cannabis company, a couple financial giants and two oil plays.
Here are several themes that are still working -- and now you can get in at a bargain.
The Chief Executive Officers of MWI Veterinary Supply, Inc. (NASDAQ: MWIV) and Campus Crest Communities, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Royal Merger Sub II Inc.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Royal Merger Sub II Inc.
Idenix shares surge as the concerns about the safety of its hepatitis C drug appear to be lifted.
The arms race to develop the next generation of hepatitis C therapies is escalating.
Investors are nervous about the safety of Inhibitex's hepatitis C drug ahead of an important safety check.
A year ago, you might not have predicted that these stocks would soar in 2011.
Traders discuss the markets and the one sector that is actually still getting attention: Beaten-up financials.
Investors did well in 2011 to own these biotech and drug stocks, all of which more than doubled in value.
Pharmasset was a leading decliner within the drugs industry, falling $4.04 (-3.2%) to $123.75 on heavy volume.
Inhibitex, Idenix Pharma shares suffer as Pharmasset discloses liver problems with one of its hepatitis C drugs.
What stock market turmoil? These managers have beaten their benchmarks over many years.
These Hep C drugmakers have taken a pummeling, so I'm entering a couple of aggressive trades here.
These speculative biotech issues have the power to defy gravity in the worst markets.
Matt Emmens retires as Vertex's CEO, replaced by board member Jeff Leiden.
TheStreet's readers make a surprising selection, prompting analyst Adam Feuerstein to call an audible.
There are five nominees, and the winner will be chosen in a week.
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Pharmasset, Inc.
Pharmasset Inc was a leading decliner within the drugs industry, falling $1.44 (-1.1%) to $130.99 on heavy volume.
Biotech columnist Adam Feuerstein looks back at a year's worth of reader questions and concerns about biotech and drug stocks.
Hewlett-Packard shares are lower in premarket trading Tuesday after the computer maker said it was 'cautious' about 2012.
Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of ...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.